4.7 Article

Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Rheumatology

Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis

Natalia Mena-Vazquez et al.

Summary: The study found that most patients with RA-ILD receiving DMARD treatment were able to stabilize lung function and control inflammatory activity well. Non-anti-TNF DMARDs reduce the risk of worsening lung disease in 90% of patients, while RA inflammatory activity and smoking are associated with worsening.

CLINICAL RHEUMATOLOGY (2021)

Article Respiratory System

Methotrexate and rheumatoid arthritis associated interstitial, Lung disease

Pierre-Antoine Juge et al.

Summary: The study found that there is no increased risk of RA-ILD associated with MTX use in patients with RA, and that ILD was detected later in MTX-treated patients.

EUROPEAN RESPIRATORY JOURNAL (2021)

Article Rheumatology

Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study

Else Helene Ibfelt et al.

Summary: Patients with rheumatoid arthritis have a higher risk of ILD compared to the general population, but there is no additional risk associated with MTX treatment.

RHEUMATOLOGY (2021)

Article Medicine, General & Internal

Predictors of Progression and Mortality in Patients with Prevalent Rheumatoid Arthritis and Interstitial Lung Disease: A Prospective Cohort Study

Natalia Mena-Vazquez et al.

Summary: This study describes a cohort of patients with RA-ILD and identifies risk factors associated with disease progression and mortality. Most patients with RA-ILD maintained stable lung function while one-third experienced worsening or died. Identifying factors related to worsening in RA-ILD is crucial for clinical management.

JOURNAL OF CLINICAL MEDICINE (2021)

Article Medicine, General & Internal

Characteristics and Predictors of Progression Interstitial Lung Disease in Rheumatoid Arthritis Compared with Other Autoimmune Disease: A Retrospective Cohort Study

Natalia Mena-Vazquez et al.

Summary: The study found that about half of patients with interstitial lung disease associated with systemic autoimmune disease stabilize or improve after a median of 5 years, but over one-third of patients die. Rheumatoid arthritis is associated with higher rates of disease progression and hospitalization in ILD, while usual interstitial pneumonia pattern, FVC%, and smoking are independent predictors for worsening of ILD-SAI.

DIAGNOSTICS (2021)

Review Immunology

Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review

Esther F. Vicente-Rabaneda et al.

Summary: Current evidence suggests that ABA may be a plausible alternative to treat RA patients with ILD. It would be highly desirable to develop prospective randomized controlled studies to confirm these findings.

AUTOIMMUNITY REVIEWS (2021)

Article Rheumatology

Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression

Marika Tardella et al.

Summary: This study aimed to evaluate the effectiveness and safety of abatacept (ABA) in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). The results showed that treatment with ABA was associated with stability or improvement in 88.6% of patients with RA-ILD. Current smoking habit and concomitant methotrexate treatment were modifiable factors associated with worsening of RA-ILD.

CLINICAL RHEUMATOLOGY (2021)

Review Respiratory System

Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

Meihua Qiu et al.

Summary: Through this systematic review and meta-analysis, older age, male sex, smoking history, higher CPI, lower DLCO% predicted, lower FVC% predicted, UIP pattern on HRCT, emphysema presence, and acute exacerbation of ILD were found to be associated with increased risk of mortality in RA-ILD patients. However, rheumatoid factor (RF) positive status was not associated with mortality.

RESPIRATORY RESEARCH (2021)

Article Rheumatology

Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience

Ivan Castellvi et al.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)

Article Medicine, General & Internal

Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis

Ji Ae Yang et al.

KOREAN JOURNAL OF INTERNAL MEDICINE (2019)

Article Medicine, General & Internal

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

K. R. Flaherty et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Respiratory System

Predicting outcomes in rheumatoid arthritis related interstitial lung disease

Joseph Jacobt et al.

EUROPEAN RESPIRATORY JOURNAL (2019)

Review Medicine, General & Internal

Cyclophosphamide for connective tissue disease-associated interstitial lung disease

Hayley Barnes et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)

Article Rheumatology

Patterns of interstitial lung disease and mortality in rheumatoid arthritis

Jorge A. Zamora-Legoff et al.

RHEUMATOLOGY (2017)

Article Rheumatology

Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis

Dam Kim et al.

RHEUMATOLOGY INTERNATIONAL (2017)

Article Respiratory System

Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease

Joshua J. Solomon et al.

EUROPEAN RESPIRATORY JOURNAL (2016)

Review Medicine, General & Internal

Rheumatoid arthritis

Josef S. Smolen et al.

LANCET (2016)

Article Cardiac & Cardiovascular Systems

Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease

Justin M. Oldham et al.

RESPIRATORY MEDICINE (2016)

Article Rheumatology

Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis

Jose Felix Restrepo et al.

CLINICAL RHEUMATOLOGY (2015)

Article Rheumatology

Abatacept Therapy in Rheumatoid Arthritis With Interstitial Lung Disease

Antonio Mera-Varela et al.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2014)

Article Respiratory System

Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome

Y. Tsuchiya et al.

EUROPEAN RESPIRATORY JOURNAL (2011)

Article Rheumatology

Incidence and Mortality of Interstitial Lung Disease in Rheumatoid Arthritis

Tim Bongartz et al.

ARTHRITIS AND RHEUMATISM (2010)

Article Critical Care Medicine

Interstitial lung disease in systemic sclerosis - A simple staging system

Nicole S. L. Goh et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)

Letter Medicine, General & Internal

Rheumatoid arthritis interstitial lung disease: Mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug

Lcslcy Ann Saketkoo et al.

ARCHIVES OF INTERNAL MEDICINE (2008)

Article Medicine, General & Internal

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition

MC Genovese et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Article Rheumatology

Pulmonary involvement in rheumatoid arthritis

A Bilgici et al.

RHEUMATOLOGY INTERNATIONAL (2005)